$16.7 Trillion is the total value of Baker Brothers Advisors's 113 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 26.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Seagen Inc. | $6,028,695,304 | +93819.5% | 46,912,266 | 0.0% | 36.20% | -13.9% | |
| INCY | Buy | Incyte Corporation | $2,903,967,271 | +120429.5% | 36,154,971 | +0.0% | 17.44% | +10.5% |
| BGNE | BeiGene, Ltd.sponsored adr | $2,566,457,206 | +163036.0% | 11,668,897 | 0.0% | 15.41% | +49.6% | |
| BMRN | BioMarin Pharmaceutical Inc. | $788,644,924 | +121983.3% | 7,620,494 | 0.0% | 4.74% | +11.9% | |
| ACAD | ACADIA Pharmaceuticals Inc. | $667,421,897 | +97210.5% | 41,923,486 | 0.0% | 4.01% | -10.8% | |
| ASND | Buy | Ascendis Pharma A/Ssponsored adr | $605,136,441 | +120665.2% | 4,954,855 | +2.1% | 3.63% | +10.7% |
| MDGL | Buy | Madrigal Pharmaceuticals, Inc. | $448,469,048 | +460179.8% | 1,545,113 | +3.1% | 2.69% | +322.1% |
| RYTM | Buy | Rhythm Pharmaceuticals, Inc. | $185,046,185 | +124480.0% | 6,354,608 | +4.8% | 1.11% | +14.2% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $145,920,191 | +91011.3% | 12,710,818 | 0.0% | 0.88% | -16.5% | |
| IMCR | Immunocore Holdings plcads | $143,858,118 | +121480.9% | 2,520,731 | 0.0% | 0.86% | +11.5% | |
| AKRO | Akero Therapeutics, Inc. | $129,787,114 | +160840.3% | 2,368,378 | 0.0% | 0.78% | +47.5% | |
| REPL | Buy | Replimune Group, Inc. | $124,529,216 | +185081.8% | 4,578,280 | +17.6% | 0.75% | +70.0% |
| KOD | Kodiak Sciences Inc. | $123,943,108 | +92406.6% | 17,310,490 | 0.0% | 0.74% | -15.2% | |
| HZNP | Horizon Therapeutics Public Ltd Co | $110,354,933 | +183775.9% | 969,727 | 0.0% | 0.66% | +68.7% | |
| ARGX | argenx SEsponsored adr | $106,132,634 | +107202.2% | 280,159 | 0.0% | 0.64% | -1.7% | |
| ABCL | AbCellera Biologics Inc. | $105,860,323 | +102327.0% | 10,450,180 | 0.0% | 0.64% | -6.1% | |
| KYMR | Kymera Therapeutics, Inc. | $71,880,432 | +114552.8% | 2,879,825 | 0.0% | 0.43% | +5.1% | |
| KDNY | Chinook Therapeutics, Inc. | $66,393,472 | +133166.7% | 2,534,102 | 0.0% | 0.40% | +22.4% | |
| Entrada Therapeutics, Inc. | $65,785,873 | +85687.1% | 4,865,819 | 0.0% | 0.40% | -21.3% | ||
| MRTX | Mirati Therapeutics, Inc. | $63,877,313 | +64777.1% | 1,409,784 | 0.0% | 0.38% | -40.5% | |
| PRLD | Prelude Therapeutics Inc. | $61,147,897 | +91277.4% | 10,123,824 | 0.0% | 0.37% | -16.2% | |
| CERS | Cerus Corporation | $58,646,587 | +101289.3% | 16,067,558 | 0.0% | 0.35% | -7.1% | |
| AVTE | Sell | Aerovate Therapeutics, Inc. | $57,922,232 | +176379.2% | 1,976,868 | -0.1% | 0.35% | +61.9% |
| IGMS | IGM Biosciences, Inc. | $53,685,295 | +74701.9% | 3,156,102 | 0.0% | 0.32% | -31.5% | |
| IMTX | Buy | Immatics N.V. | $45,179,476 | +102030.5% | 5,187,081 | +17.3% | 0.27% | -6.6% |
| NRIX | Nurix Therapeutics, Inc. | $42,625,733 | +84167.2% | 3,882,125 | 0.0% | 0.26% | -22.7% | |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $41,937,663 | +116565.3% | 2,799,577 | 0.0% | 0.25% | +7.2% | |
| SWTX | New | SpringWorks Therapeutics, Inc. | $39,757,273 | – | 1,528,538 | +100.0% | 0.24% | – |
| IDYA | IDEAYA Biosciences, Inc. | $30,314,010 | +121682.1% | 1,668,355 | 0.0% | 0.18% | +11.7% | |
| DNLI | Buy | Denali Therapeutics Inc. | $30,277,804 | +167477.0% | 1,088,738 | +84.9% | 0.18% | +54.2% |
| XENE | Xenon Pharmaceuticals Inc. | $29,637,126 | +109125.1% | 751,639 | 0.0% | 0.18% | 0.0% | |
| VERV | Verve Therapeutics, Inc. | $27,409,856 | +56231.7% | 1,416,530 | 0.0% | 0.16% | -48.3% | |
| Buy | DICE Therapeutics, Inc. | $26,900,858 | +225408.1% | 862,207 | +46.6% | 0.16% | +107.7% | |
| TVTX | Sell | Travere Therapeutics, Inc. | $25,767,113 | +31589.2% | 1,225,255 | -62.9% | 0.16% | -70.9% |
| BCYC | Bicycle Therapeutics plcsponsored ads | $24,976,894 | +127157.8% | 843,814 | 0.0% | 0.15% | +16.3% | |
| ANAB | Buy | AnaptysBio, Inc. | $24,045,885 | +220565.2% | 775,924 | +81.6% | 0.14% | +102.8% |
| KRYS | Sell | Krystal Biotech, Inc. | $23,981,162 | +81396.5% | 302,716 | -28.3% | 0.14% | -25.4% |
| DBVT | DBV Technologies S.A.sponsored adr | $22,359,824 | +86341.5% | 14,614,264 | 0.0% | 0.13% | -20.7% | |
| FGEN | Buy | FibroGen, Inc. | $22,030,880 | +207503.5% | 1,375,211 | +68.6% | 0.13% | +91.3% |
| RARE | Ultragenyx Pharmaceutical Inc. | $21,820,225 | +111781.4% | 470,974 | 0.0% | 0.13% | +2.3% | |
| HRTX | Heron Therapeutics, Inc. | $20,329,195 | +59141.2% | 8,131,678 | 0.0% | 0.12% | -45.8% | |
| 2seventy bio, Inc. | $19,327,911 | +64298.5% | 2,062,744 | 0.0% | 0.12% | -41.1% | ||
| Sell | Insmed Incorporatednote 0.75% 6/1/2028 | $19,229,604 | +52880.0% | 23,500,000 | -41.2% | 0.12% | -51.7% | |
| New | Prime Medicine, Inc. | $19,108,898 | – | 1,028,466 | +100.0% | 0.12% | – | |
| BMEA | Biomea Fusion, Inc. | $17,741,432 | +86094.6% | 2,104,559 | 0.0% | 0.11% | -20.7% | |
| BLUE | bluebird bio, Inc. | $17,298,028 | +109222.1% | 2,499,715 | 0.0% | 0.10% | 0.0% | |
| SBTX | New | ARS Pharmaceuticals, Inc. | $17,115,027 | – | 2,006,451 | +100.0% | 0.10% | – |
| NVTA | Invitae Corporation | $15,627,785 | +75509.8% | 8,402,035 | 0.0% | 0.09% | -30.4% | |
| OPT | Opthea Limitedsponsored ads | $14,425,856 | +86349.7% | 2,691,391 | 0.0% | 0.09% | -20.2% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $14,353,080 | +135716.4% | 9,830,877 | 0.0% | 0.09% | +24.6% | |
| CBAY | CymaBay Therapeutics, Inc. | $13,608,809 | +179034.0% | 2,170,464 | 0.0% | 0.08% | +64.0% | |
| New | Zymeworks Inc. | $13,428,590 | – | 1,708,472 | +100.0% | 0.08% | – | |
| Aadi Bioscience, Inc. | $12,700,776 | +90697.7% | 989,928 | 0.0% | 0.08% | -17.4% | ||
| CABA | Buy | Cabaletta Bio, Inc. | $12,432,000 | +2891062.8% | 1,344,000 | +103.0% | 0.08% | +2400.0% |
| ALT | Sell | Altimmune, Inc. | $10,751,095 | +47473.3% | 653,562 | -63.1% | 0.06% | -56.1% |
| VSTM | Verastem, Inc. | $10,863,032 | +47252.0% | 26,988,898 | 0.0% | 0.06% | -56.7% | |
| STOK | Buy | Stoke Therapeutics, Inc. | $10,235,267 | +215742.8% | 1,108,913 | +200.3% | 0.06% | +96.8% |
| CinCor Pharma, Inc. | $9,920,635 | +37346.2% | 807,212 | 0.0% | 0.06% | -65.5% | ||
| VOR | Vor Biopharma Inc. | $9,748,401 | +166996.3% | 1,465,925 | 0.0% | 0.06% | +55.3% | |
| RNA | New | Avidity Biosciences, Inc. | $9,647,813 | – | 434,782 | +100.0% | 0.06% | – |
| PACB | Pacific Biosciences of California, Inc. | $9,225,257 | +140808.2% | 1,127,782 | 0.0% | 0.06% | +27.9% | |
| RETA | Reata Pharmaceuticals, Inc.cl a | $8,508,848 | +151060.9% | 223,976 | 0.0% | 0.05% | +37.8% | |
| VERU | Veru Inc. | $8,498,577 | +45734.2% | 1,609,579 | 0.0% | 0.05% | -57.9% | |
| SMMT | New | Summit Therapeutics Inc. | $8,500,000 | – | 2,000,000 | +100.0% | 0.05% | – |
| PNT | POINT Biopharma Global Inc. | $8,522,761 | +94209.6% | 1,169,103 | 0.0% | 0.05% | -13.6% | |
| AFMD | Affimed N.V. | $8,180,069 | +60096.3% | 6,596,830 | 0.0% | 0.05% | -44.9% | |
| Invitae Corporationnote 2.0% 9/1/2024 | $8,058,143 | +98797.2% | 10,300,000 | 0.0% | 0.05% | -9.4% | ||
| CMPX | New | Compass Therapeutics, Inc. | $7,834,879 | – | 1,557,630 | +100.0% | 0.05% | – |
| DSGN | Sell | Design Therapeutics, Inc. | $7,101,264 | +29462.7% | 692,131 | -51.8% | 0.04% | -72.6% |
| New | Biohaven Ltd. | $6,609,517 | – | 476,190 | +100.0% | 0.04% | – | |
| VERA | Vera Therapeutics, Inc.cl a | $6,449,994 | +90706.6% | 333,333 | 0.0% | 0.04% | -17.0% | |
| ALEC | Buy | Alector, Inc. | $6,294,777 | +278060.7% | 681,991 | +185.1% | 0.04% | +153.3% |
| ATHA | Buy | Athira Pharma, Inc. | $5,959,080 | +192688.1% | 1,879,836 | +80.6% | 0.04% | +80.0% |
| MGNX | MacroGenics, Inc. | $5,989,205 | +193850.9% | 892,579 | 0.0% | 0.04% | +80.0% | |
| IPSC | Buy | Century Therapeutics, Inc. | $5,896,114 | +160776.2% | 1,149,340 | +210.1% | 0.04% | +45.8% |
| New | Roivant Sciences Ltd. | $5,726,057 | – | 716,653 | +100.0% | 0.03% | – | |
| Tango Therapeutics, Inc. | $5,437,500 | +200176.2% | 750,000 | 0.0% | 0.03% | +83.3% | ||
| RVMD | Revolution Medicines, Inc. | $5,293,328 | +120697.1% | 222,222 | 0.0% | 0.03% | +10.3% | |
| EWTX | Edgewise Therapeutics, Inc. | $4,470,000 | +90753.7% | 500,000 | 0.0% | 0.03% | -15.6% | |
| PRAX | New | Praxis Precision Medicines, Inc. | $4,356,150 | – | 1,830,315 | +100.0% | 0.03% | – |
| TScan Therapeutics, Inc. | $4,316,428 | +50717.4% | 2,784,792 | 0.0% | 0.03% | -53.6% | ||
| ARAV | New | Aravive, Inc. | $4,304,816 | – | 3,261,224 | +100.0% | 0.03% | – |
| CYT | Sell | Cyteir Therapeutics, Inc. | $4,111,995 | +80908.6% | 2,492,118 | -5.7% | 0.02% | -24.2% |
| NTRA | Natera, Inc. | $4,017,000 | +91570.5% | 100,000 | 0.0% | 0.02% | -17.2% | |
| TIL | Buy | Instil Bio, Inc. | $3,322,487 | +17529.7% | 5,273,789 | +35.4% | 0.02% | -83.7% |
| TLIS | Talis Biomedical Corporation | $3,398,389 | +65291.4% | 7,624,835 | 0.0% | 0.02% | -41.2% | |
| XNCR | New | Xencor, Inc. | $3,206,227 | – | 123,127 | +100.0% | 0.02% | – |
| ITOS | iTeos Therapeutics, Inc. | $2,936,257 | +102422.9% | 150,346 | 0.0% | 0.02% | -5.3% | |
| New | Kala Pharmaceuticals, Inc. | $2,930,416 | – | 76,813 | +100.0% | 0.02% | – | |
| PMVP | PMV Pharmaceuticals, Inc. | $2,801,609 | +73010.9% | 322,024 | 0.0% | 0.02% | -32.0% | |
| BCEL | Atreca, Inc. | $2,828,328 | +50897.6% | 3,532,760 | 0.0% | 0.02% | -52.8% | |
| HOOK | Buy | HOOKIPA Pharma Inc. | $2,815,183 | +87409.6% | 3,475,535 | +44.8% | 0.02% | -19.0% |
| ATRA | Atara Biotherapeutics, Inc. | $2,440,930 | +86673.2% | 744,186 | 0.0% | 0.02% | -16.7% | |
| PCVX | New | Vaxcyte, Inc. | $2,344,036 | – | 48,885 | +100.0% | 0.01% | – |
| ACHL | Achilles Therapeutics plcsponsored ads | $2,332,229 | +39726.3% | 2,591,366 | 0.0% | 0.01% | -63.2% | |
| NKTX | Nkarta, Inc. | $2,396,000 | +45416.7% | 400,000 | 0.0% | 0.01% | -58.8% | |
| FATE | Fate Therapeutics, Inc. | $2,176,363 | +44922.0% | 215,695 | 0.0% | 0.01% | -59.4% | |
| NLTX | Neoleukin Therapeutics, Inc. | $1,945,266 | +79428.5% | 3,821,740 | 0.0% | 0.01% | -25.0% | |
| KRON | Sell | Kronos Bio, Inc. | $1,941,005 | +37531.0% | 1,198,151 | -22.2% | 0.01% | -64.7% |
| ALGS | Aligos Therapeutics, Inc. | $1,978,602 | +86528.8% | 2,076,400 | 0.0% | 0.01% | -20.0% | |
| AGLE | Aeglea BioTherapeutics, Inc. | $1,534,207 | +85418.8% | 3,410,106 | 0.0% | 0.01% | -25.0% | |
| TCRR | TCR2 Therapeutics Inc. | $752,160 | +55369.0% | 753,064 | 0.0% | 0.01% | -44.4% | |
| TARA | Protara Therapeutics, Inc. | $535,118 | +90444.5% | 199,671 | 0.0% | 0.00% | -25.0% | |
| KZR | Kezar Life Sciences, Inc. | $436,100 | +81719.9% | 61,946 | 0.0% | 0.00% | 0.0% | |
| GTH | Genetron Holdings Limitedads | $509,943 | +143142.4% | 455,306 | 0.0% | 0.00% | +50.0% | |
| Sera Prognostics, Inc. | $253,968 | +78772.0% | 201,562 | 0.0% | 0.00% | 0.0% | ||
| FHTX | Foghorn Therapeutics Inc. | $287,272 | +74322.8% | 45,027 | 0.0% | 0.00% | -33.3% | |
| LPTX | Leap Therapeutics, Inc. | $251,867 | +50988.6% | 559,705 | 0.0% | 0.00% | -33.3% | |
| INSM | Insmed Incorporated | $398,601 | +92597.9% | 19,950 | 0.0% | 0.00% | -33.3% | |
| VINC | Vincerx Pharma, Inc. | $246,207 | +73836.0% | 241,379 | 0.0% | 0.00% | -50.0% | |
| Bellicum Pharmaceuticals, Inc. | $179,369 | +59889.6% | 249,123 | 0.0% | 0.00% | -50.0% | ||
| Surrozen, Inc.w exp 8/11/2026 | $45,917 | +29716.2% | 833,333 | 0.0% | 0.00% | -100.0% | ||
| LIFE | Sell | aTyr Pharma, Inc. | $18,757 | +3005.5% | 8,565 | -95.7% | 0.00% | -100.0% |
| LOGC | Exit | LogicBio Therapeutics, Inc. | $0 | – | -139,105 | -100.0% | 0.00% | – |
| OTIC | Exit | Otonomy, Inc. | $0 | – | -8,443,134 | -100.0% | -0.02% | – |
| SNDX | Exit | Syndax Pharmaceuticals, Inc. | $0 | – | -110,729 | -100.0% | -0.02% | – |
| EIGR | Exit | Eiger BioPharmaceuticals, Inc. | $0 | – | -539,851 | -100.0% | -0.03% | – |
| ALLK | Exit | Allakos Inc. | $0 | – | -703,050 | -100.0% | -0.03% | – |
| Exit | Surrozen, Inc. | $0 | – | -2,500,000 | -100.0% | -0.03% | – | |
| AMRN | Exit | Amarin Corporation plcsponsored adr | $0 | – | -5,377,113 | -100.0% | -0.04% | – |
| FLGT | Exit | Fulgent Genetics, Inc. | $0 | – | -166,619 | -100.0% | -0.04% | – |
| ZYME | Exit | Zymeworks Inc. | $0 | – | -1,708,472 | -100.0% | -0.07% | – |
| TCDA | Exit | Tricida, Inc. | $0 | – | -1,320,290 | -100.0% | -0.09% | – |
| CRNX | Exit | Crinetics Pharmaceuticals, Inc. | $0 | – | -735,716 | -100.0% | -0.10% | – |
| ALKS | Exit | Alkermes plc | $0 | – | -815,016 | -100.0% | -0.12% | – |
| RLMD | Exit | Relmada Therapeutics, Inc. | $0 | – | -495,113 | -100.0% | -0.12% | – |
| FMTX | Exit | Forma Therapeutics Holdings, Inc. | $0 | – | -1,886,760 | -100.0% | -0.25% | – |
| CCXI | Exit | ChemoCentryx, Inc. | $0 | – | -1,792,657 | -100.0% | -0.61% | – |
| GBT | Exit | Global Blood Therapeutics, Inc. | $0 | – | -3,732,502 | -100.0% | -1.66% | – |
Signatures
The EDGAR filing(s) were signed by:
- Alexandra Toohey — Chief Financial Officer
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
- Baker Brothers Advisors holdings (13F-HR)
- Baker Brothers Advisors significant holdings (13D/G)
- Baker Brothers Advisors ownership history
- Baker Brothers Advisors portfolio value
- Baker Brothers Advisors insiders transactions
- Baker Brothers Advisors filings
- Similar filers BETA
Compare quarterly holdings
Export Baker Brothers Advisors's holdings